nach oben

Erschienen in:

11.05.2021 | Original Article

Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma

verfasst von: Tao Fan, Yu Liu, Hengchang Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Zheng, Liyan Xue, Fengwei Tan, Qi Xue, Shungeng Gao, Chunxiang Li, Jie He

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

The clinical significance and comprehensive features of chemokines and their receptors in lung adenocarcinoma (LUAD) have not been clarified. We aimed to characterize the expression profiles of chemokine and chemokine receptor family members and construct a chemokine- and chemokine receptor-based prognosis signature. A total of 1511 patients with LUAD from seven independent cohorts were included in the study. The training set collected from The Cancer Genome Atlas (TCGA) database containing 468 cases. The validation was performed on the basis of six different cohorts downloaded from Gene Expression Omnibus (GEO) database. A five-chemokine- and chemokine receptor-(CXCL2, CXCL13, CCL26, CCL20, CX3CR1) based prognosis signature was constructed with TCGA dataset using LASSO Cox regression and Cox proportional hazards regression analysis. A multivariate analysis verified that this signature was an independent prognostic factor. The predictive value of this signature was further verified by other six independent cohorts and multiple clinical subtypes. We performed immune cell infiltration analysis and biological pathway analysis which provided more insight into this signature-related immune and inflammatory landscape and clarified the intrinsic molecular mechanism by which this signature could be used to predict clinical prognosis. Furthermore, we explored the close relationship between this signature and tumor mutation burden (TMB), neoantigen burden, PD-1, PD-L1, CTLA4, TIDE score, T cell-inflamed score. This signature provided a robust prognostic biomarker for LUAD and could serve as a predictor for immunotherapy response, which may be used as an important supplement to immunotherapy to achieve individualized tumor treatment by optimizing the prognostic management and immunotherapy for patients with LUAD.

Nur mit Berechtigung zugänglich

Miller K, Fidler-Benaoudia M, Keegan T, Hipp H, Jemal A, Siegel R (2020) Cancer statistics for adolescents and young adults, 2020. CA: A Cancer J Clin 70 (6): 443–459. doi:https://doi.org/10.3322/caac.21637

Kim H, Cha H, Kim J, Park W, Choi Y, Sun J, Ahn J, Ahn M, Park K, Lee S (2019) Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Eur J Cancer 120:65–74. https://doi.org/10.1016/j.ejca.2019.08.001CrossRefPubMed

Wang Q, Li M, Yang M, Yang Y, Song F, Zhang W, Li X, Chen K (2020) Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging 12(4):3312–3339. https://doi.org/10.18632/aging.102814CrossRefPubMedPubMedCentral

Yi M, Li A, Zhou L, Chu Q, Luo S, Wu K (2021) Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma. Cancer immunol immunother CII. https://doi.org/10.1007/s00262-020-02817-zCrossRefPubMed

Kalbasi A, Ribas A (2020) Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 20(1):25–39. https://doi.org/10.1038/s41577-019-0218-4CrossRefPubMed

Sharpe A, Pauken K (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153–167. https://doi.org/10.1038/nri.2017.108CrossRefPubMed

Byun D, Wolchok J, Rosenberg L, Girotra M (2017) Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195–207. https://doi.org/10.1038/nrendo.2016.205CrossRefPubMedPubMedCentral

Havel J, Chowell D, Chan T (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-xCrossRefPubMedPubMedCentral

Borghaei H, Brahmer J (2016) Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med 374(5):493–494. https://doi.org/10.1056/NEJMc1514790CrossRefPubMed

10.

Herbst R, Baas P, Kim D, Felip E, Pérez-Gracia J, Han J, Molina J, Kim J, Arvis C, Ahn M, Majem M, Fidler M, de Castro G, Garrido M, Lubiniecki G, Shentu Y, Im E, Dolled-Filhart M, Garon E (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London, England) 387(10027):1540–1550. https://doi.org/10.1016/s0140-6736(15)01281-7CrossRef

11.

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–723. https://doi.org/10.1016/j.cell.2017.01.017CrossRefPubMedPubMedCentral

12.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West A, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez A, Grogan T, Mateus C, Tomasic G, Glaspy J, Emerson R, Robins H, Pierce R, Elashoff D, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954CrossRefPubMedPubMedCentral

13.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman G, Brown M, Wucherpfennig K, Liu X (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24(10):1550–1558. https://doi.org/10.1038/s41591-018-0136-1CrossRefPubMedPubMedCentral

14.

Su W, Han H, Wang Y, Zhang B, Zhou B, Cheng Y, Rumandla A, Gurrapu S, Chakraborty G, Su J, Yang G, Liang X, Wang G, Rosen N, Scher H, Ouerfelli O, Giancotti F (2019) The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell 36(2):139-155.e110. https://doi.org/10.1016/j.ccell.2019.06.009CrossRefPubMedPubMedCentral

15.

Liao W, Overman M, Boutin A, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring D, Chang Q, Zhang J, Maru D, Maeda D, Zebala J, Kopetz S, Wang Y, DePinho R (2019) KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35(4):559-572.e557. https://doi.org/10.1016/j.ccell.2019.02.008CrossRefPubMedPubMedCentral

16.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, Kotarski J, Tarkowski R, Dou Y, Cho K, Hensley-Alford S, Munkarah A, Liu R, Zou W (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577):249–253. https://doi.org/10.1038/nature15520CrossRefPubMedPubMedCentral

17.

Bhat A, Nisar S, Maacha S, Carneiro-Lobo T, Akhtar S, Siveen K, Wani N, Rizwan A, Bagga P, Singh M, Reddy R, Uddin S, Grivel J, Chand G, Frenneaux M, Siddiqi M, Bedognetti D, El-Rifai W, Macha M, Haris M (2021) Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol Cancer 20(1):2. https://doi.org/10.1186/s12943-020-01294-3CrossRefPubMedPubMedCentral

18.

Jiang B, Liu T, Gao Y (2020) Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential. Pharmacol Ther 212:107581. https://doi.org/10.1016/j.pharmthera.2020.107581CrossRefPubMed

19.

Hsi E, Li H, Nixon A, Schöder H, Bartlett N, LeBlanc M, Smith S, Kahl B, Leonard J, Evens A, Scott D, Rimsza L, Friedberg J (2019) Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood 133(16):1762–1765. https://doi.org/10.1182/blood-2018-08-870915CrossRefPubMedPubMedCentral

20.

Teufel M, Seidel H, Köchert K, Meinhardt G, Finn R, Llovet J, Bruix J (2019) Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology 156(6):1731–1741. https://doi.org/10.1053/j.gastro.2019.01.261CrossRefPubMed

21.

Green M, Chao N, Chhabra S, Corbet K, Gasparetto C, Horwitz A, Li Z, Venkata J, Long G, Mims A, Rizzieri D, Sarantopoulos S, Stuart R, Sung A, Sullivan K, Costa L, Horwitz M, Kang Y (2016) Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol 9(1):71. https://doi.org/10.1186/s13045-016-0301-2CrossRefPubMedPubMedCentral

22.

Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y, Hoang C, Diehn M, Alizadeh A (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457. https://doi.org/10.1038/nmeth.3337CrossRefPubMedPubMedCentral

23.

Gentles A, Newman A, Liu C, Bratman S, Feng W, Kim D, Nair V, Xu Y, Khuong A, Hoang C, Diehn M, West R, Plevritis S, Alizadeh A (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938–945. https://doi.org/10.1038/nm.3909CrossRefPubMedPubMedCentral

24.

Li H, Lu H, Cui W, Huang Y, Jin X (2020) A TP53-based immune prognostic model for muscle-invasive bladder cancer. Aging. https://doi.org/10.18632/aging.202150CrossRefPubMedPubMedCentral

25.

Kang K, Xie F, Mao J, Bai Y, Wang X (2020) Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front Oncol 10:573141. https://doi.org/10.3389/fonc.2020.573141CrossRefPubMedPubMedCentral

26.

Bao X, Shi R, Zhao T, Wang Y, Anastasov N, Rosemann M, Fang W (2021) Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer immunol immunother CII 70(1):189–202. https://doi.org/10.1007/s00262-020-02669-7CrossRefPubMed

27.

Wu J, Zhao W, Zhou B, Su Z, Gu X, Zhou Z, Chen S (2018) TSNAdb: a database for tumor-specific neoantigens from immunogenomics data analysis. Genomics Proteomics Bioinform 16(4):276–282. https://doi.org/10.1016/j.gpb.2018.06.003CrossRef

28.

Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3(11):1529–1537. https://doi.org/10.1001/jamaoncol.2017.1609CrossRefPubMedPubMedCentral

29.

Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao P, Cai Z, Chen Y, Liu M, Pang X (2020) Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Investig 130(4):1752–1766. https://doi.org/10.1172/jci124049CrossRefPubMedPubMedCentral

30.

Yang J, Gadgeel S, Sequist L, Wu C, Papadimitrakopoulou V, Su W, Fiore J, Saraf S, Raftopoulos H, Patnaik A (2019) Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J thoracic oncol official publicat Int Assoc Study Lung Cancer 14(3):553–559. https://doi.org/10.1016/j.jtho.2018.11.028CrossRef

31.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res BCR 11(2):R15. https://doi.org/10.1186/bcr2234CrossRefPubMed

32.

Ma J, Zhang J, Yang D, Ma X (2020) Identification of novel prognosis-related genes in the endometrial cancer immune microenvironment. Aging 12(21):22152–22173. https://doi.org/10.18632/aging.104083CrossRefPubMedPubMedCentral

33.

Zhang J, Gu J, Guo S, Huang W, Zheng Y, Wang X, Zhang T, Zhao W, Ni B, Fan Y, Wang H (2020) Establishing and validating a pathway prognostic signature in pancreatic cancer based on miRNA and mRNA sets using GSVA. Aging 12(22):22840–22858. https://doi.org/10.18632/aging.103965CrossRefPubMedPubMedCentral

34.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung H, Kindler H, Lopez-Martin J, Miller W, Italiano A, Kao S, Piha-Paul S, Delord J, McWilliams R, Fabrizio D, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang Y (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21(10):1353–1365. https://doi.org/10.1016/s1470-2045(20)30445-9CrossRefPubMed

35.

Wang Z, Duan J, Cai S, Han M, Dong H, Zhao J, Zhu B, Wang S, Zhuo M, Sun J, Wang Q, Bai H, Han J, Tian Y, Lu J, Xu T, Zhao X, Wang G, Cao X, Li F, Wang D, Chen Y, Bai Y, Zhao J, Zhao Z, Zhang Y, Xiong L, He J, Gao S, Wang J (2019) Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 5(5):696–702. https://doi.org/10.1001/jamaoncol.2018.7098CrossRefPubMedPubMedCentral

36.

Kishton R, Lynn R, Restifo N (2020) Strength in numbers: identifying neoantigen targets for cancer immunotherapy. Cell 183(3):591–593. https://doi.org/10.1016/j.cell.2020.10.011CrossRefPubMed

37.

Chae Y, Viveiros P, Lopes G, Sukhadia B, Sheikh M, Saravia D, Florou V, Sokol E, Frampton G, Chalmers Z, Ali S, Ross J, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin S, Oh M, Anker J, Park L, Wang V, Chuang J, Park W (2019) Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J thoracic oncol offic publicat Int Assoc Study Lung Cancer 14(10):1807–1817. https://doi.org/10.1016/j.jtho.2019.06.016CrossRef

38.

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad M, Hellmann M, Lin J, Friedlander T, Bushway M, Balogh K, Sciuto T, Kohler V, Turnbull S, Besada R, Curran R, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting Y, Dong J, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary L, Moles M, Manson K, Greshock J, Khondker Z, Fritsch E, Rooney M, DeMario M, Gaynor R, Srinivasan L (2020) A phase ib trial of personalized neoantigen therapy plus anti-pd-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183(2):347-362.e324. https://doi.org/10.1016/j.cell.2020.08.053CrossRefPubMed

39.

Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, Hu DX, Jackson JJ, Pookot D, Sanchez J, Brovarney M, Wadsworth A, Chian D, Wustrow D, Kassner PD, Cutler G, Wong B, Brockstedt DG, Talay O (2020) Tumors establish resistance to immunotherapy by regulating T-reg recruitment via CCR4. J Immunother Cancer 8(2):11. https://doi.org/10.1136/jitc-2020-000764CrossRef

40.

Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P (2016) Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer 4:21. https://doi.org/10.1186/s40425-016-0125-1CrossRefPubMedPubMedCentral

41.

Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal B, Dy G, Ernstoff M, Ito F (2021) T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun 12(1):1402. https://doi.org/10.1038/s41467-021-21619-0CrossRefPubMedPubMedCentral

42.

Yamauchi T, Hoki T, Oba T, Saito H, Attwood K, Sabel M, Chang A, Odunsi K, Ito F (2020) CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. JCI insight. https://doi.org/10.1172/jci.insight.133920CrossRefPubMedPubMedCentral

43.

Natsume M, Shimura T, Iwasaki H, Okuda Y, Hayashi K, Takahashi S, Kataoka H (2020) Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2-VEGFA axis. Br J Cancer 123(3):459–470. https://doi.org/10.1038/s41416-020-0898-3CrossRefPubMedPubMedCentral

44.

Hu J, Zhao Q, Kong L, Wang J, Yan J, Xia X, Jia Z, Heimberger A, Li S (2021) Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. https://doi.org/10.1126/sciadv.abc2511CrossRefPubMedPubMedCentral

45.

Inoue C, Miki Y, Saito R, Hata S, Abe J, Sato I, Okada Y, Sasano H (2019) PD-L1 induction by cancer-associated fibroblast-derived factors in lung adenocarcinoma cells. Cancers. https://doi.org/10.3390/cancers11091257CrossRefPubMedPubMedCentral

46.

Goswami S, Chen Y, Anandhan S, Szabo P, Basu S, Blando J, Liu W, Zhang J, Natarajan S, Xiong L, Guan B, Yadav S, Saci A, Allison J, Galsky M, Sharma P (2020) ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Translat Medicine. https://doi.org/10.1126/scitranslmed.abc4220CrossRef

47.

Hippe A, Braun S, Oláh P, Gerber P, Schorr A, Seeliger S, Holtz S, Jannasch K, Pivarcsi A, Buhren B, Schrumpf H, Kislat A, Bünemann E, Steinhoff M, Fischer J, Lira S, Boukamp P, Hevezi P, Stoecklein N, Hoffmann T, Alves F, Sleeman J, Bauer T, Klufa J, Amberg N, Sibilia M, Zlotnik A, Müller-Homey A, Homey B (2020) EGFR/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer 123(6):942–954. https://doi.org/10.1038/s41416-020-0943-2CrossRefPubMedPubMedCentral

48.

Gordy J, Luo K, Kapoor A, Kim E, Ayeh S, Karakousis P, Markham R (2020) Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model. Cancer immunol immunotherap CII 69(4):569–580. https://doi.org/10.1007/s00262-019-02471-0CrossRef

49.

Lan Q, Lai W, Zeng Y, Liu L, Li S, Jin S, Zhang Y, Luo X, Xu H, Lin X, Chu Z (2018) CCL26 participates in the prl-3-induced promotion of colorectal cancer invasion by stimulating tumor-associated macrophage infiltration. Mol Cancer Ther 17(1):276–289. https://doi.org/10.1158/1535-7163.Mct-17-0507CrossRefPubMed

50.

Khan S, Khan S, Luo X, Fattah F, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber D (2019) Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer 120(1):63–68. https://doi.org/10.1038/s41416-018-0155-1CrossRefPubMed

51.

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera O, De Marinis F, Turna H, Lee J, Ballinger M, Kowanetz M, He P, Chen D, Sandler A, Gandara D (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England) 389(10066):255–265. https://doi.org/10.1016/s0140-6736(16)32517-xCrossRef

52.

Woo S, Corrales L, Gajewski T (2015) The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 36(4):250–256. https://doi.org/10.1016/j.it.2015.02.003CrossRefPubMedPubMedCentral

Titel: Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma
verfasst von: Tao Fan
Yu Liu
Hengchang Liu
Liyu Wang
He Tian
Yujia Zheng
Bo Zheng
Liyan Xue
Fengwei Tan
Qi Xue
Shungeng Gao
Chunxiang Li
Jie He
Publikationsdatum: 11.05.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 12/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-02944-1

Springer Medizin

Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2021

Immune infiltrate diversity confers a good prognosis in follicular lymphoma

Megakaryoblastic leukemia: a study on novel role of clinically significant long non-coding RNA signatures in megakaryocyte development during treatment with phorbol ester

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients

Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism

A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie